Study adds to efforts to find more effective anti-inflammatory drugs

September 27, 2012, Cincinnati Children's Hospital Medical Center

Researchers have discovered a previously unknown function for a protein that could add to the expanding arsenal of potential new drugs for battling inflammation and tissue fibrosis in a number of disease processes.

Scientists from Cincinnati Children's Hospital Medical Center report Sept. 27 in Developmental Cell that, a protein called TRPC6 mediates a molecular pathway critical to the body's repair processes following various forms of injury caused by disease.

After injury – such as that caused by a heart attack – the TRPC6-controlled pathway prompts cells called fibroblasts to change into myofibroblasts, according to the study.

Myofibroblasts secrete a substance called extracellular matrix, an important building block needed for wound healing and tissue remodeling, which includes inflammation and scarring.

"Our study suggests that a TRPC inhibitor could be a good anti-fibrotic or anti- in , muscular dystrophy, and other diseases where becomes a problem," said Jeffery Molkentin, PhD, principal investigator and a scientist at the Cincinnati Children's Heart Institute and Howard Hughes Medical Institute. "As well, activation of the TRPC pathway with an agonist compound could be used in select situations to enhance wound healing."

Although the body needs a certain amount of inflammation and scarring to heal and return to normal function, in the process can get stuck in the "on" mode. This can lead to fibrosis (the buildup of excess connective tissues) and cause serious . Effectively and safely controlling complex inflammation processes in these situations remains an unmet clinical need, and is also the impetus behind a concerted effort in biomedical research to find new .

Researchers on the current study were encouraged by how effectively the TRPC6 pathway (TRPC6-calcineurin-NFAT) appeared to influence the transformation of fibroblasts into myofibroblasts, the secretion of extracellular matrix, wound healing and fibrosis. The authors wrote that identification of this cell repair signaling mechanism "offers an additional avenue for developing targeted intervention points in fibrotic diseases."

Calcineurin is a calcium-dependent enzyme involved in the immune system, the regulation of T-cells and also important in the function of heart cells. NFAT (nuclear factor of activated T-cells) is a family of proteins important to the immune system and the development of different tissues in the body.

Including first author Jennifer Davis, PhD. – a member of Molkentin's laboratory – the researchers started their study by running a genomic screen of molecules that regulate the transformation of fibroblast cells into myofibroblasts. The screen and subsequent laboratory tests identified TRPC6 as a promising candidate. Prior to the current study, TRPC6 had not been associated with fibrosis, although it has been linked to other cellular functions in kidneys, skin cells and hippocampal neurons of the brain.

The scientists used a virus expressing TRPC6 to infect cell cultures of mouse embryonic fibroblasts, rat cardiac fibroblasts and human dermal fibroblasts. TRPC6-infected fibroblasts fully activated the transformation to myofibroblasts, while fibroblasts lacking TRPC6 were resistant to transformation. In TRPC-6 gene deleted mice, the animals showed impaired dermal and cardiac wound healing after injury.

Molkentin said there are TRPC inhibitors in the early stage drug development pipeline, although their initial design has not targeted heart disease, inflammation or fibrosis. He added the current study may provide an impetus for widening the development focus to include these medical needs.

Explore further: Newly identified protein function protects cells during injury

Related Stories

Newly identified protein function protects cells during injury

June 7, 2012
Scientists have discovered a new function for a protein that protects cells during injury and could eventually translate into treatment for conditions ranging from cardiovascular disease to Alzheimer's.

New drug successfully halts fibrosis in animal model of liver disease

August 7, 2012
A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver ...

Researchers learn how lung fibrosis begins and could be treated

June 27, 2011
An invasive cell that leads to fibrosis of the lungs may be stopped by cutting off its supply of sugar, according to researchers at Duke University Medical Center.

Recommended for you

Chronic inflammation causes loss of muscle mass during aging

January 12, 2018
People start losing muscle mass at the age of 40—about some 10 percent of the total muscle mass for each 10-year period, which may lead to fall-related injuries, slowing metabolism and reduced quality of life. Today, very ...

Breathing exercises help asthma patients with quality of life

December 13, 2017
A study led by the University of Southampton has found that people who continue to get problems from their asthma, despite receiving standard treatment, experience an improved quality of life when they are taught breathing ...

Study highlights the need for research into prevention of inflammatory bowel disease

December 7, 2017
Countries in Africa, Asia, the Middle East and South America have seen a rise in incidence of inflammatory bowel disease as they have become increasingly industrialised and westernised, a new study has found.

Air pollution can increase asthma risk in adults, even at low levels

November 24, 2017
Living close to a busy road can be bad for your respiratory health if you are middle aged, new Australian research has found.

Evidence found of oral bacteria contributing to bowel disorders

October 20, 2017
(Medical Xpress)—An international team of researchers has found evidence that suggests certain types of oral bacteria may cause or exacerbate bowel disorders. In their paper published in the journal Science, the group describes ...

New compound discovered in fight against inflammatory disease

September 22, 2017
A 10-year study by University of Manchester scientists for a new chemical compound that is able to block a key component in inflammatory illness has ended in success.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.